Skip to main content
. 2021 Feb;10(2):965–980. doi: 10.21037/tlcr-21-146

Figure 4.

Figure 4

Association between PD-L1 and B3GNT3 expression in EGFR-TKI–sensitive HCC827 (A) and PC9 cell lines (B) by 48 hours continuous intervention of gefitinib. **P<0.01, ****P<0.0001. PD-L1, programmed cell death-ligand 1; B3GNT3, beta-1,3-N-acetylglucosaminyltransferase 3; EGFR-TKI; epidermal growth factor receptor tyrosine kinase inhibitor